FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559352151> ?p ?o ?g. }

• W2559352151 abstract "Abstract Most patients with chronic myeloid leukemia (CML) express the BCR-ABL transcript with the b2a2 (e13a2) or b3a2 (e14a2) junctions corresponding to the major BCR gene breakpoint cluster region (M-BCR). We and others have reported that a small proportion of CML patients (1–2%), which have breakpoints that fall outside of the M-BCR, giving rise to shortened BCR-ABL transcripts (m-BCR, e6a2, b2a3, b3a3) or longer BCR-ABL transcripts (μ-BCR). The clinical and hematologic features of 8 additional patients with e8a2 BCR-ABL fusions transcripts have been recently reviewed (Demehri et al, Leukemia 2005) and, according to the authors, could be associated with thrombocytosis and a worse prognosis than common M-BCR transcripts. Here, we report three additional CML patients with an e8a2 BCR-ABL fusion transcript treated with imatinib and who achieved hematologic, cytogenetic remission. Molecular studies allowed us to quantify this rare BCR-ABL fusion mRNA. All the patients showed a major molecular response with a reduction of at least 3 logs compared to initial samples at a median follow-up of 34 months (range 30–39). None of the cases (patients #1, 2 and 3) described here showed thrombocytosis at diagnosis. The diagnosis of chronic phase CML was based on typical peripheral blood findings and cytogenetics. In all cases, standard karyotyping demonstrated a t(9;22)(q34;q11), but further molecular analysis revealed an atypical e8a2 BCR-ABL fusion gene. In case #1, FISH using the LSI-bcr/abl ES probe (Vysis) showed a typical M-BCR picture which was different with the case previously described. Multiplex RT-PCR for BCR-ABL and sequencing showed a fusion between BCR exon e8 and ABL exon a2, with a 55 base pair (bp) insert, which perfectly matched an inverted sequence from ABL intron Ib. Most of the patients with an e8a2 BCR-ABL fusion transcript previously described seem to be associated with a worse prognosis because none of them treated with interferon achieved even a minor response. Here, all the patients are alive, achieved complete cytogenetic and major molecular responses with a prolonged follow up, confirming thus the efficacy of imatinib mesylate in patients with rare BCR-ABL transcripts. Of note, in cases #2 and #3, the major molecular response was obtained after increasing the dosage of imatinib (400 to 600 mg/day), suggesting that those patients may require higher doses of imatinib to achieve proper molecular response. The aggressive clinical course of these leukemias could be shrouded by appropriate targeted therapy. A longer follow-up and the analysis of a large cohort of patients with e8a2 BCR-ABL fusions are necessary to analyse the clinical outcome of these patients. The study of these unusual transcripts is essential to gain more insights of their molecular pathological function and a more comprehensive survey of the different functions of the BCR-ABL chimeric protein." @default.
• W2559352151 created "2016-12-08" @default.
• W2559352151 creator A5007725714 @default.
• W2559352151 creator A5010797184 @default.
• W2559352151 creator A5012805294 @default.
• W2559352151 creator A5045283637 @default.
• W2559352151 creator A5052564121 @default.
• W2559352151 creator A5053984329 @default.
• W2559352151 creator A5064103067 @default.
• W2559352151 creator A5077014294 @default.
• W2559352151 creator A5077614586 @default.
• W2559352151 creator A5085325813 @default.
• W2559352151 creator A5087886055 @default.
• W2559352151 date "2005-11-16" @default.
• W2559352151 modified "2023-10-01" @default.
• W2559352151 title "Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib." @default.
• W2559352151 doi "https://doi.org/10.1182/blood.v106.11.4830.4830" @default.
• W2559352151 hasPublicationYear "2005" @default.
• W2559352151 type Work @default.
• W2559352151 sameAs 2559352151 @default.
• W2559352151 citedByCount "0" @default.
• W2559352151 crossrefType "journal-article" @default.
• W2559352151 hasAuthorship W2559352151A5007725714 @default.
• W2559352151 hasAuthorship W2559352151A5010797184 @default.
• W2559352151 hasAuthorship W2559352151A5012805294 @default.
• W2559352151 hasAuthorship W2559352151A5045283637 @default.
• W2559352151 hasAuthorship W2559352151A5052564121 @default.
• W2559352151 hasAuthorship W2559352151A5053984329 @default.
• W2559352151 hasAuthorship W2559352151A5064103067 @default.
• W2559352151 hasAuthorship W2559352151A5077014294 @default.
• W2559352151 hasAuthorship W2559352151A5077614586 @default.
• W2559352151 hasAuthorship W2559352151A5085325813 @default.
• W2559352151 hasAuthorship W2559352151A5087886055 @default.
• W2559352151 hasConcept C104317684 @default.
• W2559352151 hasConcept C111829193 @default.
• W2559352151 hasConcept C125418893 @default.
• W2559352151 hasConcept C126322002 @default.
• W2559352151 hasConcept C138626823 @default.
• W2559352151 hasConcept C170493617 @default.
• W2559352151 hasConcept C2777583451 @default.
• W2559352151 hasConcept C2778461978 @default.
• W2559352151 hasConcept C2778729363 @default.
• W2559352151 hasConcept C2778904597 @default.
• W2559352151 hasConcept C2779788118 @default.
• W2559352151 hasConcept C3019892230 @default.
• W2559352151 hasConcept C42362537 @default.
• W2559352151 hasConcept C43907098 @default.
• W2559352151 hasConcept C502942594 @default.
• W2559352151 hasConcept C54355233 @default.
• W2559352151 hasConcept C71924100 @default.
• W2559352151 hasConcept C86803240 @default.
• W2559352151 hasConcept C89560881 @default.
• W2559352151 hasConceptScore W2559352151C104317684 @default.
• W2559352151 hasConceptScore W2559352151C111829193 @default.
• W2559352151 hasConceptScore W2559352151C125418893 @default.
• W2559352151 hasConceptScore W2559352151C126322002 @default.
• W2559352151 hasConceptScore W2559352151C138626823 @default.
• W2559352151 hasConceptScore W2559352151C170493617 @default.
• W2559352151 hasConceptScore W2559352151C2777583451 @default.
• W2559352151 hasConceptScore W2559352151C2778461978 @default.
• W2559352151 hasConceptScore W2559352151C2778729363 @default.
• W2559352151 hasConceptScore W2559352151C2778904597 @default.
• W2559352151 hasConceptScore W2559352151C2779788118 @default.
• W2559352151 hasConceptScore W2559352151C3019892230 @default.
• W2559352151 hasConceptScore W2559352151C42362537 @default.
• W2559352151 hasConceptScore W2559352151C43907098 @default.
• W2559352151 hasConceptScore W2559352151C502942594 @default.
• W2559352151 hasConceptScore W2559352151C54355233 @default.
• W2559352151 hasConceptScore W2559352151C71924100 @default.
• W2559352151 hasConceptScore W2559352151C86803240 @default.
• W2559352151 hasConceptScore W2559352151C89560881 @default.
• W2559352151 hasLocation W25593521511 @default.
• W2559352151 hasOpenAccess W2559352151 @default.
• W2559352151 hasPrimaryLocation W25593521511 @default.
• W2559352151 hasRelatedWork W1852122703 @default.
• W2559352151 hasRelatedWork W1969189716 @default.
• W2559352151 hasRelatedWork W2107030941 @default.
• W2559352151 hasRelatedWork W2162756755 @default.
• W2559352151 hasRelatedWork W2202725014 @default.
• W2559352151 hasRelatedWork W2409919881 @default.
• W2559352151 hasRelatedWork W2558351990 @default.
• W2559352151 hasRelatedWork W2559352151 @default.
• W2559352151 hasRelatedWork W2743367850 @default.
• W2559352151 hasRelatedWork W3006090897 @default.
• W2559352151 isParatext "false" @default.
• W2559352151 isRetracted "false" @default.
• W2559352151 magId "2559352151" @default.
• W2559352151 workType "article" @default.